Skip to main content
Top

05-09-2014 | Ophthalmologic cancers | Article

11. Retinoblastoma: Intravenous Chemotherapy

Authors: Rajkumar Venkatramani, MD, MS, Rima Fuad Jubran, MD, MPH

Publisher: Springer Berlin Heidelberg

Abstract

The management of patients with intraocular retinoblastoma has changed dramatically in the past 20 years with the introduction of primary systemic chemotherapy. Before 1990, systemic chemotherapy had been used to treat patients with extraocular disease, with less than optimal results. In the early 1990s, several investigators from North America and the United Kingdom began using chemotherapy agents that were effective against central nervous system tumors, to treat intraocular retinoblastoma. The rationale was to achieve decrease in intraocular tumor volume with systemic chemotherapy (chemoreduction) so as to allow better tumor kill with local treatment using photocoagulation and cryotherapy. Further, it was hoped that the use of chemotherapy would help to eliminate the need for external beam radiation therapy (EBRT) in this patient population susceptible to second malignancy.
Literature
1.
White L. Chemotherapy in retinoblastoma: current status and future directions. Am J Pediatr Hematol Oncol. 1991;13(2):189–201.PubMedCrossRef
2.
Shields CL, De Potter P. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1330–8.PubMedCrossRef
3.
Murphree AL, Villablanca JG, Deegan 3rd WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1348–56.PubMedCrossRef
4.
Kingston JE, Hungerford JL. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1339–43.PubMedCrossRef
5.
Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272–9.PubMedCrossRef
6.
Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100(24):1771–9.PubMedCrossRef
7.
Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 2003;21(10):2019–25.PubMedCrossRef
8.
Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114(11):1321–8.PubMedCrossRef
9.
Dunkel IJ, Lee TC, Shi W, et al. A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer. 2007;49(5):643–8.PubMedCrossRef
10.
Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118(22):5663–70.PubMedCrossRefPubMedCentral
11.
Chantada G, Fandiño A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40(3):158–61.PubMedCrossRef
12.
Antoneli CBG, Steinhorst F, De Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98(6):1292–8.PubMedCrossRef
13.
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41–53, viii.PubMedCrossRef
14.
Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–80.PubMedCrossRef
15.
Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18(1):12–7.PubMed
16.
Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol. 2002;133(5):657–64.PubMedCrossRef
17.
Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer. 2012. doi:10.​1002/​pbc.​24303.PubMed
18.
Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106(10):1947–50.PubMedCrossRef
19.
Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120–4.PubMedCrossRef
20.
Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41–8.PubMed
21.
Chantada GL, Dunkel IJ, De Dávila MTG, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88(8):1069–73.PubMedCrossRefPubMedCentral
22.
Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002;120(7):923–31.PubMedCrossRef
23.
Eagle Jr RC. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203–9.PubMed
24.
Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129(11):1422–7.PubMedCrossRef
25.
Chintagumpala M, Langholz B, Eagle RC Jr, et al. A large prospective trial of children with unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: a Children’s Oncology Group (COG) study. J Clin Oncol. 2012;30(suppl; abstr 9515).
26.
Jubran RF, Erdreich-Epstein A, Butturini A, Murphree AL, Villablanca JG. Approaches to treatment for extraocular retinoblastoma: Children’s Hospital Los Angeles experience. J Pediatr Hematol Oncol. 2004;26(1):31–4.PubMedCrossRef
27.
Chantada G, Doz F, Antoneli CBG, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47(6):801–5.PubMedCrossRef
28.
Chantada GL, Guitter MR, Fandiño AC, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer. 2009;52(2):218–22.PubMedCrossRef
29.
Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997;33(14):2368–75.PubMedCrossRef
30.
Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89(10):2117–21.PubMedCrossRef
31.
Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005;35(8):763–6.PubMedCrossRef
32.
Dunkel IJ, Chan HSL, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer. 2010;55(1):149–52.PubMed
33.
De Potter P, Shields CL, Shields JA. Clinical variations of trilateral retinoblastoma: a report of 13 cases. J Pediatr Ophthalmol Strabismus. 1994;31(1):26–31.PubMed
34.
Amoaku WM, Willshaw HE, Parkes SE, Shah KJ, Mann JR. Trilateral retinoblastoma. A report of five patients. Cancer. 1996;78(4):858–63.PubMedCrossRef
35.
Dunkel IJ, Jubran RF, Gururangan S, et al. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer. 2010;54(3):384–7.PubMedCrossRef
36.
Blommaert FA, Van Dijk-Knijnenburg HC, Dijt FJ, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry. 1995;34(26):8474–80.PubMedCrossRef
37.
Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50(2):223–6.PubMedCrossRef
38.
Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637–43.PubMedCrossRef
39.
Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17(2):569–77.PubMed
40.
Correia JJ. Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther. 1991;52(2):127–47.PubMedCrossRef
41.
Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol. 2008;126(6):862–5.PubMedCrossRef
42.
Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol. 2012;30(10):1023–4.PubMedCrossRef
43.
Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114(7):1378–83.PubMedCrossRef
44.
Nishimura S, Sato T, Ueda H, Ueda K. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol. 2001;19(21):4182–3.PubMed
45.
Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer. 2012;59(1):121–5.PubMedCrossRef